Exhibit 2.2
AMENDED AND
RESTATED
ASSET PURCHASE
AGREEMENT
for VANIQA®
between
WOMEN FIRST HEALTHCARE,
INC.
as Seller,
and
SKINMEDICA, INC., or its
designee
as Purchaser
Dated as of June 24,
2004
TABLE OF CONTENTS
|
|
|
|
|
SECTION 1. DEFINITIONS AND
INTERPRETATION
|
|
1
|
|
|
|
|
Section 1.01. Defined Terms.
|
|
1
|
|
|
|
|
Section 1.02. Other Defined Terms.
|
|
10
|
|
|
|
|
Section 1.03. Interpretation.
|
|
10
|
|
|
|
|
Section 1.04. Singular; Plural; Use of
Words.
|
|
11
|
|
|
|
|
SECTION 2. CONSUMMATION OF
TRANSACTION
|
|
11
|
|
|
|
|
Section 2.01. Acquired Assets.
|
|
11
|
|
|
|
|
Section 2.02. Assumed Liabilities.
|
|
12
|
|
|
|
|
Section 2.03. Purchase Price.
|
|
13
|
|
|
|
|
Section 2.04. Closing; Deliveries.
|
|
15
|
|
|
|
|
Section 2.05. Assumption of Assumed
Contracts.
|
|
16
|
|
|
|
|
Section 2.06. Risk of Loss.
|
|
17
|
|
|
|
|
Section 2.07. Bankruptcy Court
Approval.
|
|
17
|
|
|
|
|
SECTION 3. REPRESENTATIONS AND WARRANTIES OF
SELLER
|
|
17
|
|
|
|
|
Section 3.01. Organization, Etc.
|
|
17
|
|
|
|
|
Section 3.02. Authority; Execution and Delivery;
Enforceability.
|
|
18
|
|
|
|
|
Section 3.03. Consents and Approvals; No
Violations.
|
|
18
|
|
|
|
|
Section 3.04. Financial Statements and Books and
Records.
|
|
18
|
|
|
|
|
Section 3.05. Absence of Certain
Changes.
|
|
19
|
|
|
|
|
Section 3.06. Undisclosed
Liabilities.
|
|
19
|
|
|
|
|
Section 3.07. Taxes.
|
|
19
|
|
|
|
|
Section 3.08. Title of Assets.
|
|
19
|
|
|
|
|
Section 3.09. Intellectual Property.
|
|
19
|
|
|
|
|
Section 3.10. Material Contracts.
|
|
20
|
|
|
|
|
Section 3.11. Compliance with Law.
|
|
21
|
|
|
|
|
Section 3.12. Accounts Receivable.
|
|
21
|
|
|
|
|
Section 3.13. Inventory.
|
|
21
|
|
|
|
|
Section 3.14. Customers and
Representatives.
|
|
21
|
|
|
|
|
Section 3.15. Regulatory Matters.
|
|
21
|
|
|
|
|
Section 3.16. Litigation.
|
|
22
|
|
|
|
|
Section 3.17. Environmental Matters.
|
|
23
|
|
|
|
|
Section 3.18. Brokers or Finders.
|
|
23
|
|
|
|
|
Section 3.19. No Other Seller Representations or
Warranties.
|
|
23
|
|
|
|
|
|
|
|
|
SECTION 4. REPRESENTATIONS AND WARRANTIES OF
PURCHASER
|
|
24
|
|
|
|
|
Section 4.01. Organization, Etc.
|
|
24
|
|
|
|
|
Section 4.02. Authority; Execution and Delivery;
Enforceability.
|
|
24
|
|
|
|
|
Section 4.03. Consents and Approvals; No
Violations.
|
|
24
|
|
|
|
|
Section 4.04. Litigation.
|
|
25
|
|
|
|
|
Section 4.05. Brokers or Finders.
|
|
25
|
|
|
|
|
Section 4.06. Sufficient Funds.
|
|
25
|
|
|
|
|
Section 4.07. “As Is”
Transaction.
|
|
25
|
|
|
|
|
Section 4.08. No Other Purchaser Representations
or Warranties.
|
|
25
|
|
|
|
|
SECTION 5. ACTIONS PRIOR TO THE
CLOSING
|
|
26
|
|
|
|
|
Section 5.01. Confidentiality.
|
|
26
|
|
|
|
|
Section 5.02. Taxes.
|
|
26
|
|
|
|
|
Section 5.03. Bulk Transfer Laws.
|
|
26
|
|
|
|
|
Section 5.04. Returns Handling.
|
|
26
|
|
|
|
|
Section 5.05. Consents and Approvals.
|
|
27
|
|
|
|
|
Section 5.06. Conduct of the Business Pending
the Closing.
|
|
28
|
|
|
|
|
Section 5.07. Financial Statements.
|
|
29
|
|
|
|
|
Section 5.08. Certain Contracts
|
|
29
|
|
|
|
|
SECTION 6. BANKRUPTCY AND OTHER
COVENANTS
|
|
29
|
|
|
|
|
Section 6.01. Bankruptcy Court Filings and
Approvals.
|
|
29
|
|
|
|
|
Section 6.02. Assumption of Contracts: Notice to
Reject Designated Contracts.
|
|
29
|
|
|
|
|
Section 6.03. Release of Liens.
|
|
30
|
|
|
|
|
Section 6.04. Transfer of Assets.
|
|
30
|
|
|
|
|
Section 6.05. [Intentionally Omitted]
|
|
30
|
|
|
|
|
Section 6.06. [Intentionally Omitted]
|
|
30
|
|
|
|
|
Section 6.07. No Solicitation; Bankruptcy Court
Procedures.
|
|
30
|
|
|
|
|
Section 6.08. Overbid Procedures.
|
|
31
|
|
|
|
|
Section 6.09. Break-Up Fee and Expense
Reimbursement.
|
|
31
|
|
|
|
|
SECTION 7. CONDITIONS TO OBLIGATIONS
|
|
32
|
|
|
|
|
Section 7.01. Conditions to Obligations of
Purchaser.
|
|
32
|
|
|
|
|
Section 7.02. Conditions to Obligations of
Seller.
|
|
33
|
|
|
|
|
Section 7.03. Conditions to Obligations of
Purchaser and Seller.
|
|
33
|
|
|
|
|
SECTION 8. ACTIONS AFTER THE CLOSING
|
|
33
|
|
|
|
|
Section 8.01. Transfer of Regulatory
Matters.
|
|
33
|
|
|
|
|
Section 8.02. Effective Time of
Closing.
|
|
34
|
|
|
|
|
Section 8.03. Insurance.
|
|
34
|
ii
|
|
|
|
|
|
|
|
Section 8.04. Access to Information.
|
|
34
|
|
|
|
|
Section 8.05. No Use of Certain
Names.
|
|
35
|
|
|
|
|
Section 8.06. Customer Notifications.
|
|
35
|
|
|
|
|
Section 8.07. Further Assurances and
Services.
|
|
35
|
|
|
|
|
Section 8.08. Reasonable Access to Records and
Certain Personnel.
|
|
36
|
|
|
|
|
Section 8.09. Adverse Event
Reporting.
|
|
36
|
|
|
|
|
Section 8.10. Post-Closing Matters.
|
|
37
|
|
|
|
|
SECTION 9. TERMINATION; TERMINATION
PAYMENT
|
|
38
|
|
|
|
|
Section 9.01. Termination.
|
|
38
|
|
|
|
|
Section 9.02. Effect of Termination.
|
|
39
|
|
|
|
|
SECTION 10. SURVIVAL OF REPRESENTATIONS AND
WARRANTIES; INDEMNIFICATION FROM ESCROW ACCOUNT
|
|
39
|
|
|
|
|
Section 10.01. Survival.
|
|
39
|
|
|
|
|
Section 10.02. Indemnification by
Seller.
|
|
39
|
|
|
|
|
Section 10.03. Indemnification by
Purchaser.
|
|
40
|
|
|
|
|
Section 10.04. Calculation of Losses.
|
|
41
|
|
|
|
|
Section 10.05. Procedures.
|
|
41
|
|
|
|
|
Section 10.06. Sole Remedy; No Additional
Representations.
|
|
42
|
|
|
|
|
Section 10.07. Limitations on
Liability.
|
|
42
|
|
|
|
|
Section 10.08. Cooperation.
|
|
43
|
|
|
|
|
SECTION 11. MISCELLANEOUS
|
|
43
|
|
|
|
|
Section 11.01. Notices.
|
|
43
|
|
|
|
|
Section 11.02. Descriptive Headings.
|
|
44
|
|
|
|
|
Section 11.03. Counterparts.
|
|
44
|
|
|
|
|
Section 11.04. Entire Agreement.
|
|
44
|
|
|
|
|
Section 11.05. Fees and Expenses.
|
|
44
|
|
|
|
|
Section 11.06. Injunctive Relief.
|
|
44
|
|
|
|
|
Section 11.07. Assignment.
|
|
45
|
|
|
|
|
Section 11.08. Successors and
Assigns.
|
|
45
|
|
|
|
|
Section 11.09. Severability.
|
|
45
|
|
|
|
|
Section 11.10. Waiver of Jury Trial.
|
|
45
|
|
|
|
|
Section 11.11. Governing Law; Exclusive
Jurisdiction.
|
|
45
|
|
|
|
|
Section 11.12. Schedules, Exhibits and Other
Agreements.
|
|
46
|
|
|
|
|
Section 11.13. Amendments and
Waivers.
|
|
46
|
iii
AMENDED AND
RESTATED
ASSET PURCHASE
AGREEMENT
THIS AMENDED AND RESTATED ASSET
PURCHASE AGREEMENT (this
“ Agreement ”) dated as of June 24, 2004 (the
“ Agreement Date ”) is between Women First
HealthCare, Inc., a Delaware corporation (“ Seller
” or “ WFHC ”), and SkinMedica, Inc., a
Delaware corporation, or its designee (subject to and in accordance
with Section 11.08 hereof) (“ Purchaser
”).
RECITALS
WHEREAS, Seller is engaged in the
business, directly or indirectly through its Affiliates (as defined
in Section 1.01), of distributing, marketing and selling current
presentations and formulations of the prescription form of
VANIQA® (eflornithine hydrochloride) Cream, 13.9% (the “
Product ”) for use in the Indication (as defined in
Section 1.01) (such business as conducted by Seller, the “
Business ”);
WHEREAS, Seller has filed a
voluntary petition for relief under Chapter 11 of the Bankruptcy
Code (as defined in Section 1.01) in the Bankruptcy Court (as
defined in Section 1.01);
WHEREAS, Seller intends to request
that the Bankruptcy Court authorize and approve the transactions
contemplated herein through the Chapter 11 Case (as defined in
Section 1.01) pursuant to, among others, Sections 105, 363 and 365
of the Bankruptcy Code and terms of an auction commenced pursuant
to the Bidding Procedures Order entered May 19, 2004;
WHEREAS, Seller desires to sell to
Purchaser, and Purchaser desires to purchase from Seller,
Seller’s right, title and interest in and to the Acquired
Assets (as defined in Section 1.01);
WHEREAS, Purchaser desires to
assume, and Seller desires to have assumed, the Assumed Liabilities
(as defined in Section 2.02(a)); and
WHEREAS, this Agreement supersedes
the Asset Purchase Agreement dated April 29, 2004 between Purchaser
and Seller, as amended by Amendment No. 1 thereto, which agreement
shall be of no further force or effect.
NOW, THEREFORE, in consideration of
the premises and the mutual covenants and promises contained
herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties
hereby agree as follows:
SECTION 1.
DEFINITIONS AND
INTERPRETATION
Section 1.01. Defined
Terms .
For purposes of this
Agreement:
“ Acquired Assets
” shall mean (a) the Intellectual Property, (b) the Books and
Records, (c) the Marketing Materials, (d) the Inventory, (e) the
Regulatory Documentation, (f) the Assumed Contracts, (g) the
content (including any data or databases, the design, and look and
feel) of, and any software owned by Seller used to operate, the web
sites having any of the URLs listed on Schedule 3.09(a)
(excluding all Names), and (h) all rights directly relating to the
foregoing, including all claims, counterclaims, credits, causes of
action, choses in action, rights of recovery and rights of setoff,
but specifically excluding the Excluded Assets.
“ Affiliate ”
shall mean, with respect to any Person, any Person which, directly
or indirectly, controls, is controlled by or is under common
control with, the specified Person. For purposes of this
definition, the term “ control ” as applied to
any Person, shall mean the possession, directly or indirectly, of
the power to direct or cause the direction of the management of
that Person, whether through ownership of voting securities or
otherwise.
“ Alternative
Transaction ” shall mean a transaction or series of
related transactions pursuant to which Seller accepts, and the
Bankruptcy Court confirms, a Qualified Bid for the Acquired Assets
or any group of assets that includes the Acquired Assets, other
than that of Purchaser, as the highest or best offer.
“ Assignment of
Copyrights ” shall mean the Assignment of Copyrights
agreement executed by Seller and Purchaser in substantially the
form of Exhibit A .
“ Assignment of Internet
Names ” shall mean the Assignment of Internet Names
agreement executed by Seller and Purchaser in substantially the
form of Exhibit B .
“ Assignment of Seller
Patents ” shall mean the Assignment of Patents agreement
executed by Seller and Purchaser in substantially the form of
Exhibit C .
“ Assignment of
Trademarks ” shall mean the Assignment of Trademarks
agreement executed by Seller and Purchaser in substantially the
form of Exhibit D .
“ Assumed Contracts
” shall mean the Contracts listed on Exhibit E
.
“ Assumption Agreement
” shall mean the Assumption Agreement executed by Purchaser
in substantially the form of Exhibit F .
“ Auction ” shall
mean the auction that Seller will conduct at the time and place set
forth in the Bidding Procedures Order in the event that Seller
receives one or more Qualified Bids in addition to
Purchaser’s Qualified Bid under this Agreement.
“ Avoidance Action
” shall mean all rights and avoidance claims of Seller
arising under Chapter 5 of the Bankruptcy Code.
“ Balance Sheet ”
shall mean the balance sheet of Seller as of December 31, 2003
included in the Financial Statements.
“ Bankruptcy Code
” shall mean title 11 of the United States Code, as amended
and in effect from time to time.
“ Bankruptcy Court
” shall mean the United States Bankruptcy Court for the
District of Delaware having jurisdiction over Seller and its
assets.
“ Bidding Procedures
” shall have the meaning set forth in the Bidding Procedures
Order.
“ Bidding Procedures
Order ” shall mean the order of the Bankruptcy Court,
pursuant to Sections 105(a), 363 and 365 of the Bankruptcy Code:
(a) authorizing and scheduling the Auction; (b) approving
procedures for the submission of Qualified Bids; (c) in the case of
any subsequent Qualified Bids, approving the initial overbid of at
least $1,250,000 and further incremental overbids of at least
$100,000;
2
(d) approving the Break-Up Fee and Expense
Reimbursement; (e) scheduling a hearing to consider approval of
such sale; and (f) approving the form and manner of notice of the
Auction procedures and sale hearing, which order, entered by the
Bankruptcy Court on May 19, 2004, is attached as Exhibit G
.
“ Bill of Sale ”
shall mean the Bill of Sale in substantially the form of Exhibit
H .
“ BMS ” shall
mean Bristol-Myers Squibb Company.
“ BMS Know-How ”
shall have the meaning set forth in the Master Vaniqa® License
Agreement.
“ BMS Manufacturing
Know-How ” shall have the meaning set forth in that
certain Supply Agreement dated June 25, 2002, as amended pursuant
to the First Amendment to Supply Agreement dated September 8, 2003,
between WFHC and BMS.
“ Books and Records
” shall mean (a) all books, records and recorded information,
including customer, physician and supplier lists, of Seller or its
Affiliates primarily related to the Business as of the Closing Date
and (b) laboratory books, batch records, stability and clinical
studies and regulatory files, if any, related to the Seller
Patents.
“ Business Day ”
shall mean a day other than Saturday, Sunday or any other day on
which banking institutions in New York, New York or San Diego,
California are required or authorized to close by law or executive
order.
“ CERCLA ” shall
have the meaning given in the definition of “ Hazardous
Substance or Waste .”
“ C.F.R. ” shall
mean the U.S. Code of Federal Regulations.
“ Chapter 11 Case
” shall mean the bankruptcy case commenced by Seller under
Chapter 11 of the Bankruptcy Code in the Bankruptcy
Court.
“ Cleanup ” shall
mean all actions required to: (A) cleanup, remove, treat or
remediate Hazardous Materials in the indoor or outdoor environment;
(B) prevent the Release of Hazardous Materials so that they do not
migrate, endanger or threaten to endanger public health or welfare
of the indoor or outdoor environment; (C) perform pre-remedial
studies and investigations and post-remedial monitoring and care;
or (D) respond to any government requests for information or
documents in any way relating to cleanup, removal, treatment or
remediation or potential cleanup, removal, treatment or remediation
of Hazardous Materials in the indoor or outdoor
environment.
“ Contract ”
shall mean any agreement, contract, evidence of indebtedness,
purchase order, lease, security or pledge agreement, or license to
which Seller is a party or is bound and which relates primarily to
the Business or Seller’s operations of distributing,
marketing and selling the Product, whether oral or written, but
excluding all Employee Plans.
“ Copyrights ”
shall mean the copyrights, copyright registrations and applications
held in Seller’s name set forth on Schedule 3.09(a ),
and any other copyrights or works of authorship owned by Seller
which are used or held for use primarily in the conduct or
operation of the Business, both domestic and foreign.
“ Cure Costs ”
shall mean all costs required to be paid pursuant to Section 365 of
the Bankruptcy Code in connection with the assumption and
assignment of the Assumed Contracts.
“ DDMAC ” shall
have the meaning given in the definition of “ Regulatory
Documentation .”
3
“ Default ” shall
mean (i) a breach of or default under any Contract, (ii) the
occurrence of an event that with the passage of time or the giving
of notice or both would constitute a breach of or default under any
Contract, or (iii) the occurrence of an event that with or without
the passage of time or the giving of notice or both would give rise
to a right of termination, renegotiation or acceleration under any
Contract.
“ Employee Plan ”
shall mean each employee benefit plan as defined in Section 3(3) of
the Employee Retirement Income Security Act of 1974, as amended,
maintained, used or held for use in the conduct or operation of the
Business covering any employee of Seller.
“ Environmental Claim
” shall mean any claim, action, cause of action,
investigation or notice (written or oral) by any Person alleging
potential liability (including, without limitation, potential
liability for investigatory costs, Cleanup costs, governmental
response costs, natural resources damages, property damages,
personal injuries, or penalties) arising out of, based on or
resulting from (A) the presence, or Release into the indoor or
outdoor environment, of any Hazardous Materials at any location,
whether or not owned or operated, used or held for use in the
conduct or operation of the Business, or (B) circumstances forming
the basis of any violation, or alleged violation, of any
Environmental Laws.
“ Environmental Laws
” shall mean all federal, state, local and foreign laws and
regulations relating to pollution or protection of human health or
the environment, including without limitation, laws relating to
Releases or threatened Releases of Hazardous Materials into the
indoor or outdoor environment (including, without limitation,
ambient air, surface water, ground water, land surface or
subsurface strata) or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, Release,
disposal, transport or handling of Hazardous Materials and all laws
and regulations with regard to record keeping, notification,
disclosure and reporting requirements respecting Hazardous
Materials, and all laws relating to endangered or threatened
species of fish, wildlife and plants and the management or use of
natural resources.
“ Escrow Amount ”
shall mean an amount equal to $1,000,000.
“ Excluded Assets
” shall mean all assets, properties and rights of Seller and
any of its Affiliates of whatever kind and nature, real or
personal, tangible or intangible, that are not used or held for use
primarily in the operation or conduct of the Business.
“ Expense Reimbursement
” shall mean all of the reasonable, documented out-of-pocket
costs and expenses, including reasonable attorneys’ fees, and
fees of other professionals, incurred on or after March 1, 2004 by
Purchaser for or in connection with the negotiation, documentation
and implementation of this Agreement and the transactions
contemplated hereby and participation in the Chapter 11 Case, in an
amount not to exceed $250,000 in the aggregate.
“ FDA ” shall
mean the United States Food and Drug Administration, or any
successor entity.
“ Final Order ”
shall mean an order issued and entered by the Bankruptcy Court or
by any other court of competent jurisdiction which has not been
reversed, stayed, modified, or amended and as to which (i) the time
to appeal or petition for review, rehearing or certiorari has
expired and no appeal or petition for review, rehearing or
certiorari has been timely filed, or (ii) any appeal or petition
for review, rehearing or certiorari has been finally decided and no
further appeal or petition for review, rehearing or certiorari can
been taken or granted.
“ Financial Statements
” shall mean the audited consolidated balance sheets of
Seller as of December 31, 2003 and 2002 and the related
consolidated statements of operations, stockholders’ equity
(deficit), and cash flows for each of the three years in the period
ended December 31, 2003 included in Seller’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2003.
4
“ GAAP ” shall
mean United States generally accepted accounting principles as in
effect on the Agreement Date.
“ Gillette ”
shall mean The Gillette Company, a Delaware corporation.
“ Gillette Know-How
” shall have the meaning set forth in the Master Vaniqa®
License Agreement.
“ Gillette Patents
” shall mean: (a) U.S. Patents 4,720,489 and 5,648,394; (b)
all divisionals, continuations, continuations-in-part, reissues,
extensions, reexaminations, or renewal applications related to the
foregoing; and (c) all foreign equivalents to any of the
foregoing.
“ Governmental Entity
” shall mean any court of competent jurisdiction,
legislature, governmental agency, administrative agency or
commission or other governmental authority or other instrumentality
of the United States or any other country, or any state, county,
city or other political subdivision thereof.
“ Hazardous Materials
” shall mean (i) all substances defined as Hazardous
Substances, Oils, Pollutants or Contaminants in the National Oil
and Hazardous Substances Pollution Contingency Plan (“
NOHSPCP ”), 40 C.F.R. §300.5; (ii) all substances
which are designated pursuant to Section 311(b)(2)(A) of the
Federal Water Pollution Control Act (“ FWPCA ”),
33 U.S.C. § 1251 et seq.; (iii) any element, compound,
mixture, solution, or substance which is designated pursuant to
Section 102 of the Comprehensive Environmental Response,
Compensation and Liability Act (“ CERCLA ”), 42
U.S.C. § 9601 et seq.; (iv) any hazardous waste having the
characteristics which are identified under or listed pursuant to
Section 3001 of the Resource Conservation and Recovery Act (“
RCRA ”), 42 U.S.C. § 6901 et seq.; (v) any toxic
pollutant listed under Section 307(a) of the FWPCA; (vi) any
hazardous air pollutant which is listed under Section 112 of the
Clean Air Act, 42 U.S.C. § 7401 et seq.; (vii) any imminently
hazardous chemical substance or mixture with respect to which
action has been taken pursuant to Section 7 of the Toxic Substances
Control Act, 15 U.S.C. § 2601 et seq.; (viii) petroleum, crude
oil, or any fraction thereof; (ix) exposed asbestos and (x)
dangerous, toxic, or hazardous substances or similar terms under
any other federal, state, provincial or local Environmental
Law.
“ IND ” shall
have the meaning given in the definition of “ Regulatory
Documentation .”
“ Indication ”
shall mean the treatment of unwanted facial hair in
women.
“ Intellectual Property
” shall mean, collectively, (a) the Know-How, (b) the
Trademarks, (c) the Copyrights, (d) the Trade Dress, (e) the
Internet Names and (f) the Seller Patents.
“ Internet Names
” shall mean the web addresses, domain names, e-mail
addresses and phone numbers held in Seller’s name set forth
in Schedule 3.09(a ), and the applications and registrations
therefor.
“ Inventory ”
shall mean the units of finished Product packaged for commercial
sale as of the Closing Date.
“ Know-How ”
shall mean the Manufacturing Know-How and the WFHC
Know-How.
“ Knowledge ” or
“ Known ” shall mean with respect to Seller, the
actual knowledge of each of the individuals set forth on
Schedule 1.01(a) .
5
“ Liability ”
shall mean any liability, claim, demand or obligation, whether
known or unknown, whether asserted or unasserted, whether absolute
or contingent, whether accrued or unaccrued, whether liquidated or
unliquidated, and whether due or to become due.
“ Lien ” shall
mean any lien (statutory or otherwise), claim, charge, option,
security interest, pledge, mortgage, deed of trust, restriction,
financing statement or similar encumbrance of any kind or nature
whatsoever (including any conditional sale or other title retention
agreement and any lease having substantially the same effect as any
of the foregoing and any assignment or deposit arrangement in the
nature of a security device), as well as all other liens, claims,
encumbrances and interests in property which a debtor may sell
“free and clear” of under applicable bankruptcy
law.
“ Manufacturing
Know-How ” shall mean the percentages and specifications
of ingredients, the manufacturing processes, specifications,
technology, inventions, assays, quality control and testing
procedures, know-how and trade secrets owned by Seller and used to
manufacture, formulate, test and package the Product for sale,
marketing and distribution as of the Closing Date. For the sake of
clarity, none of the foregoing information shall be included in
Know-How to the extent that such information is covered by any
claim of any Patent.
“ Marketing Materials
” shall mean all marketing materials, marketing research
data, customer and sales information, product literature,
promotional materials and data, advertising and display materials
and all training materials in whatever medium (e.g., audio, visual
or print) and primarily related to the Business or the Acquired
Assets as of the Closing Date.
“ Master Vaniqa®
License Agreement ” shall mean that certain License
Agreement dated June 25, 2002, among WFHC, Gillette and BMS in
effect as of the Effective Date (as defined therein), a copy of
which is attached hereto as Exhibit I .
“ Master Vaniqa®
Purchase Agreement ” shall mean that certain Asset
Purchase Agreement for Vaniqa® dated June 25, 2002 among WFHC,
Gillette, BMS and the Partnership, a copy of which is attached
hereto as Exhibit J .
“ Material Adverse
Effect ” shall mean, with respect to a Person, any event,
circumstance or effect, whether individually or in the aggregate,
that does or is reasonably expected to have a material adverse
effect (a) on the business, operations, financial condition, assets
or properties, or Liabilities of such Person or (b) on the right or
ability of such Person to consummate the transactions contemplated
hereby, provided , however , a material adverse
effect shall not include general economic or industry circumstances
or events and, with respect to Seller, shall not include changes or
effects resulting directly or indirectly from the filing by Seller
of the Chapter 11 Case.
“ Names ” shall
mean “Women First HealthCare” and variations and
derivates thereof, any other logos, trademarks, trade names or
service marks of Seller other than the Trademarks, and any NDC
Numbers of Seller.
“ NDA ” shall
mean any new drug application filed pursuant to the requirements of
the FDA, as more fully defined in 21 C.F.R. § 314.5 et
seq. , and any equivalent application filed with any
Governmental Entity.
“ NDC Number ”
shall mean the unique, identifying number assigned to a drug
product, including the labeler code, product code and package code,
in connection with the drug listing requirements of Section 510(j)
of the FD&C Act and applicable FDA rules and
regulations.
“ NOHSPCP ” shall
have the meaning given in the definition of “ Hazardous
Substance or Waste .”
6
“ Order ” shall
mean any decree, order, injunction, rule, judgment, or consent of
or by any court or Governmental Entity.
“ Ordinary Course of
Business ” shall mean the operation of the Business by
Seller in the usual and ordinary course in a manner substantially
similar to the manner in which Seller operated during the fiscal
year ended December 31, 2003.
“ Partnership ”
shall mean Westwood-Squibb Colton Holdings Partnership.
“ Patents ” shall
mean patents and patent applications, and all additions, divisions,
continuations, continuations-in-part, provisionals, continued
prosecution applications, substitutions, reissues, extensions,
registrations and renewals of any of the foregoing, both domestic
and foreign.
“ Permits ” shall
mean all transferable licenses, permits, approvals, certificates of
occupancy, authorizations, operating permits, registrations, plans
and the like relating exclusively to the conduct of the Business
for which consent is obtained.
“ Permitted Liens
” shall mean each of the following: (i) Liens for Taxes not
yet due and payable as of the Closing Date; (ii) statutory Liens
which secure amounts not due and payable as of the Closing Date
that arise, and which are customarily discharged, in the ordinary
course of business; (iii) the Shire License Agreement; and (iv)
easements, right of way and similar imperfections of title and
encumbrances, if any, that individually or in the aggregate, do not
materially impair the Acquired Assets or their use in the
Business.
“ Person ” shall
mean any individual, group, corporation, partnership or other
organization or entity, including any Governmental
Entity.
“ Pipeline Number
” shall mean the number of tubes of Product equal to (i) the
estimated number of tubes of Product held by wholesalers, chain
warehouses and pharmacies (calculated for pharmacies as one-half of
the April 2004 withdrawal rate per NDC or reasonably equivalent
prescription data) as of April 30, 2004 (the “ April
Estimate ”) plus (ii) the number of tubes of
Product, if any, shipped by Seller to wholesalers, chain warehouses
and pharmacies on or after May 1, 2004 and before June 25, 2004
minus (iii) the product of (A) the Withdrawal Rate times (B)
the number of days from and including May 1, 2004 until (but
excluding) June 25, 2004 minus (iv) the Repurchase Tubes (as
defined in Section 2.02(b)) minus (v) any tubes of Product
returned to Seller by wholesalers, chain warehouses or pharmacies
on or after May 1, 2004 and before June 25, 2004 and included in
the calculation of Liability to Customers (as defined in Section
2.03(a)(i)). Each of Seller and Purchaser acknowledges and agrees
that the April Estimate shall be 115,958.
“ Product Registrations
” shall mean the NDAs (including any marketing authorization
approvals) and comparable regulatory filings in any country and
approvals for the Product held in Seller’s name as set forth
in Schedule 1.01(b).
“ Qualified Bid ”
shall have the meaning set forth in the Bidding Procedures
Order.
“ RCRA ” shall
have the meaning given in the definition of “Hazardous
Materials.”
“ Registered Intellectual
Property ” shall mean any Intellectual Property that is
the subject of an application, certificate, filing, registration or
other document issued, filed with or recorded by any Governmental
Entity, other public legal authority or internet domain registrars
or registries.
7
“ Regulation ”
shall mean any law, statute, regulation, ruling, rule or Order of,
administered or enforced by or on behalf of, any court or
governmental authority.
“ Regulatory
Documentation ” shall mean (a) all regulatory filings and
supporting documents, chemistry, manufacturing and controls data
and documentation, preclinical and clinical studies and tests, (b)
the NDA and all regulatory files and foreign equivalents related
thereto, (c) all records maintained under record keeping or
reporting requirements of the FDA or any other Governmental Entity
including all investigational new drug (“IND”)
applications, IND annual and safety reports, drug master files, FDA
warning letters, FDA Notices of Adverse Finding Letters, FDA audit
reports (including any responses to such reports), any
correspondence with the Department of Drug Marketing, Advertising
and Communications (the “DDMAC”), adverse event files,
periodic safety update reports, complaint files, and annual product
quality reviews, (d) the complete complaint, adverse event and
medical inquiry filings with respect to the Product, in each case
held by Seller or its Affiliates related to the Business, including
the Product Registrations, and (e) any FDA Form 483’s
concerning the Product issued to any manufacturer of the Product or
any adverse notice delivered to a manufacturer concerning the
Product.
“ Related Instruments
” shall mean the Confidentiality Agreement, Bill of Sale,
Assumption Agreement, Assignment of Trademarks, Assignment of
Copyrights, Assignment of Seller Patents, Assignment of Internet
Names, Seller’s Officer’s Certificate,
Purchaser’s Officer’s Certificate and any other
agreements entered into in connection with the transaction
contemplated in this Agreement.
“ Release ” shall
mean any release, spill, emission, discharge, leaking, pumping,
injection, deposit, disposal, discharge, dispersal, leaching or
migration into the indoor or outdoor environment (including,
without limitation, ambient air, surface water, groundwater and
surface or subsurface strata) or into or out of any property,
including the movement of Hazardous Materials through or in, the
air, soil, surface water, groundwater or property.
“ Requirements of Laws
” shall mean any applicable foreign, federal, state and local
laws, statutes, regulations, rules, codes, ordinances, enforceable
judgments, injunctions, decrees and orders, permits, approvals,
treaties, enacted, adopted, issued or promulgated by any
Governmental Entity or common law then in effect.
“ Sale Hearing ”
shall mean the hearing of the Bankruptcy Court to approve the
transactions contemplated by this Agreement.
“ Sale Order ”
shall mean the order of the Bankruptcy Court to be entered pursuant
to, among others, Sections 105, 363 and 365 of the Bankruptcy Code
approving the conveyance of the Acquired Assets on the terms and
conditions set forth in this Agreement to Purchaser, in form and
substance acceptable to Purchaser, which among other things
determines (i) that the provisions of Section 363(n) of the
Bankruptcy Code have not been violated, and (ii) that Purchaser
will not incur any liability as a successor to Seller or its
business and which contains those terms required by Section
7.01(d), and such other terms and conditions as Purchaser may
require, including terms and conditions customarily employed in
sale orders entered in transactions of this nature.
“ Seller Patents
” shall mean (a) U.S. Patent Application Serial Number
60/315,832 and U.S. Patent Application Serial Number 60/312,657,
(b) all divisionals, continuations, continuations-in-part,
improvements, reissues, extensions, reexaminations, or renewal
applications related to the foregoing, (c) all foreign equivalents
to any of the foregoing, and (d) all applications that relate to
any of the foregoing. All such Patents and foreign equivalents
granted or filed as of the date of this Agreement are set forth on
Schedule 3.09(a).
“ Shire ” shall
mean Shire Pharmaceuticals Ireland Limited.
8
“ Shire License
Agreement ” shall mean that certain License and Supply
Agreement dated as of December 15, 2003 between WFHC and
Shire.
“ Taxes ” or
“ Tax ” in the singular form, shall mean any and
all taxes, levies or other like assessments, including income,
transfer, gains, gross receipts, excise, inventory, property (real,
personal or intangible), custom duty, sales, use, license,
withholding, payroll, employment, capital stock and franchise
taxes, imposed by any Governmental Entity.
“ Tax Return ”
shall mean any report, return or other information filed with any
taxing authority with respect to Taxes imposed upon or attributable
to the operations of the Business.
“ Third Party ”
shall mean a Person who or which is neither a party hereto nor an
Affiliate of a party hereto.
“ Trade Dress ”
shall mean the trade dress and packaging held and used by Seller or
held for use by Seller in the conduct or operation of the Business
as of the Closing Date.
“ Trademarks ”
shall mean all trade names, logos, common law trademarks and
service marks, trademark and service mark registrations and
applications therefor held in Seller’s name which are used or
held for use in the Business as set forth on Schedule 3.09(a),
together with the goodwill associated therewith, both domestic and
foreign.
“ United States ”
or “ U.S. ” shall mean the fifty (50) states of
the United States of America, the District of Columbia, Puerto Rico
and all possessions and territories of the United States of
America.
“ U.S.C. ” shall
mean the United States Code.
“ WFHC Know-How ”
shall mean product specifications, processes, product designs,
plans, trade secrets, ideas, concepts, inventions, manufacturing,
engineering and other manuals and drawings, standard operating
procedures, formulae, flow diagrams, chemical, pharmacological,
toxicological, pharmaceutical, physical, analytical, safety,
quality assurance, quality control and clinical data, technical
information, research records, and all other confidential or
proprietary technical and business information which is used
primarily in the Business, in each case owned by WFHC or its
Affiliates as of the Closing Date; provided, however, that
“WFHC Know-How” shall not include the Gillette
Know-How, BMS Know-How, BMS Manufacturing Know-How or Manufacturing
Know-How. For the sake of clarity, none of the foregoing
information shall be included in know-how to the extent that such
information is covered by any claim of any Patents.
“ Withdrawal Rate
” shall mean the quotient of (i) number of tubes estimated or
presumed to have been dispensed during April 2004 based on the
April 2004 withdrawal rate per NDC or reasonably equivalent
prescription data divided by (ii) thirty (30). Each of Purchaser
and Seller acknowledges and agrees that the Withdrawal Rate shall
be 581.
9
Section 1.02. Other Defined
Terms .
The following terms have the
meanings set forth in the Sections set forth below:
|
|
|
|
|
Term
|
|
Section
|
|
Agreement
|
|
Preamble
|
|
Agreement Date
|
|
Preamble
|
|
Assumed Liabilities
|
|
2.02(a)
|
|
Business
|
|
Recitals
|
|
Break Up Fee
|
|
6.09
|
|
Closing
|
|
2.04(a)
|
|
Closing Date
|
|
2.04(a)
|
|
Confidentiality Agreement
|
|
5.01
|
|
Conflict
|
|
3.03(a)
|
|
Customers
|
|
3.14
|
|
Deposit
|
|
2.03(b)
|
|
Disclosure Schedule
|
|
Preamble to Section 3
|
|
Escrow Account
|
|
2.03(a)(ii)
|
|
Excluded Liabilities
|
|
2.02(b)
|
|
FD&C Act
|
|
3.11
|
|
Financing Commitment
|
|
4.06
|
|
Indemnified Party
|
|
10.05(a)
|
|
Indemnifying Party
|
|
10.05(a)
|
|
Liability to Customers
|
|
2.03(a)(i)
|
|
Losses
|
|
10.02(a)
|
|
Non-Serious Adverse Event
|
|
8.09(c)
|
|
Proceedings
|
|
3.09(c)
|
|
Product
|
|
Recitals
|
|
Purchase Price
|
|
2.03(a)(i)
|
|
Purchaser
|
|
Preamble
|
|
Purchaser Indemnified Parties
|
|
10.02(a)
|
|
Purchaser’s Officer’s
Certificate
|
|
2.04(c)(ii)
|
|
Representatives
|
|
3.14
|
|
Repurchase Liability
|
|
2.02(b)
|
|
Repurchase Tubes
|
|
2.02(b)
|
|
Restricted Persons
|
|
6.07(b)
|
|
Seller
|
|
Preamble
|
|
Seller’s Officer’s
Certificate
|
|
2.04(b)
|
|
Serious Adverse Event
|
|
8.09(c)
|
|
Supply Agreement
|
|
2.03(a)(i)
|
|
Third Party Claim
|
|
10.05(a)
|
|
Topping Offer
|
|
6.08
|
|
Transfer Taxes
|
|
5.02(a)
|
|
Transition Services
|
|
8.07(b)
|
|
Tube Liability Certificate
|
|
2.04(d)
|
|
WFHC
|
|
Preamble
|
Section 1.03.
Interpretation .
In the event of an ambiguity or a
question of intent or interpretation arises, this Agreement shall
be construed as if drafted jointly by the parties and no
presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of the authorship of any provisions of this
Agreement.
10
Section 1.04. Singular;
Plural; Use of Words .
The definitions of the terms in this
Agreement shall apply equally to the singular and plural forms of
the terms defined. Whenever the context may require, any pronoun
shall include the corresponding masculine, feminine and neuter
forms. The words “ include ,” “
includes ” and “ including ” shall
be deemed to be followed by the phrase “ without
limitation .” The word “ will ” shall
be construed to have the same meaning and effect as the word
“ shall .” Unless the context requires otherwise
(a) any definition of or reference to any agreement, instrument or
other document in this Agreement shall be construed as referring to
such agreement, instrument or other document as from time to time
amended, supplemented or otherwise modified (subject to any
restrictions on such amendments, supplements or modifications set
forth in this Agreement), (b) any reference in this Agreement to
any Person shall be construed to include the Person’s
successors and assigns, (c) the words “ herein
,” “ hereof ” and “ hereunder
,” and words of similar import, shall be construed to refer
to this Agreement in its entirety and not to any particular
provision of this Agreement, and (d) all references in this
Agreement to Sections, Exhibits or Schedules shall be construed to
refer to Sections, Exhibits and Schedules of this Agreement. Any
law or statute defined or referred to herein shall mean such law or
statute as from time to time amended, modified or supplemented,
including by succession of comparable successor laws and
statutes.
SECTION 2.
CONSUMMATION OF
TRANSACTION
Section 2.01. Acquired
Assets .
(a) Transfer of Acquired
Assets.
|
|
(i)
|
On the terms
and subject to the conditions of this Agreement, at the Closing,
Seller shall sell, assign, transfer, convey and deliver to
Purchaser, and Purchaser shall purchase, acquire and accept from
Seller, all the right, title and interest of Seller as of the
Closing Date in, to and under the Acquired Assets, free and clear
of all Liens, other than Permitted Liens, in accordance with
Section 105 and Sections 363(b), (f), (k) and (m), Sections 365(a),
(b), (f), and (k) of the Bankruptcy Code.
|
|
|
(ii)
|
Purchaser
acknowledges and agrees that the Acquired Assets do not include (A)
any rights in or to any Patents other than the Seller Patents, (B)
any rights in or to any other intellectual property other than the
Intellectual Property or (C) any rights in or to any Excluded
Assets.
|
|
|
(iii)
|
Purchaser
acknowledges and agrees that the Acquired Assets shall be subject
in all respects to the license rights previously granted by Seller
to Shire under the Shire License Agreement, provided that contract
is assumed and assigned to Purchaser by court order.
|
|
|
(iv)
|
Notwithstanding
anything contained in this Agreement to the contrary, (A) from and
after the Closing, Seller and its respective Affiliates shall
retain all of their respective rights, title and interest in and to
the Excluded Assets, and (B) Seller may retain an archival copy of
all Books and Records, Marketing Materials, Regulatory
Documentation and other documents or materials conveyed by Seller
hereunder.
|
(b) No Assignment .
Notwithstanding anything to the contrary contained in this
Agreement, except as provided in the Sale Order, if the sale,
assignment, transfer, conveyance or delivery
11
or attempted sale, assignment, transfer,
conveyance or delivery to Purchaser of any asset that would be an
Acquired Asset, other than any Assumed Contract listed on
Exhibit E hereto or any asset or assets that are material to
the conduct of the Business on the whole, is (i) prohibited by any
Requirements of Laws or (ii) would require any authorizations,
approvals, consents or waivers from a Third Party or Governmental
Entity and such authorizations, approvals, consents or waivers
shall not have been obtained prior to the Closing or obviated by
the Sale Order, then in either case the Closing shall proceed
without the sale, assignment, transfer, conveyance or delivery of
such asset and this Agreement shall not constitute a sale,
assignment, transfer, conveyance or delivery of such asset. In the
event that the Closing proceeds without the sale, assignment,
transfer, conveyance or delivery of any such asset, then following
the Closing, the parties shall use their reasonable commercial
efforts, and cooperate with each other in good faith, to obtain
promptly such authorizations, approvals, consents or waivers so as
to convey such assets to Purchaser, for no additional
consideration; provided , however , that Seller shall
not be required to pay any consideration to obtain any such
authorization, approval, consent or waiver. Pending such
authorization, approval, consent or waiver, the parties shall
cooperate with each other in good faith (at their own expense) in
any reasonable and lawful arrangements that will provide to
Purchaser the benefits of use of such asset and to Seller the
benefits, including any indemnities, that, in each case, it would
have obtained had the asset been conveyed to Purchaser at the
Closing. To the extent that Purchaser seeks to obtain and is
provided the benefits of an asset pursuant to this Section 2.01(b),
from and after the Closing Date Purchaser shall perform the
obligations of Seller with respect to such asset that arise after
the Closing Date and satisfy any related obligations and
Liabilities with respect to such asset that arise after the Closing
Date, that in each case, but for the lack of an authorization,
approval, consent or waiver to assign such obligations or
Liabilities to Purchaser, would be Assumed Liabilities. If
authorization, approval, consent or waiver for the sale,
assignment, transfer, conveyance or delivery of any such asset not
sold, assigned, transferred, conveyed or delivered at the Closing
is obtained, Seller shall assign, transfer, convey and deliver such
asset to Purchaser at no additional cost to Purchaser, as
aforesaid.
Section 2.02. Assumed
Liabilities .
(a) Upon the terms and subject to
the conditions of this Agreement, Purchaser shall assume, effective
as of the Closing Date, and Purchaser shall pay, perform and
discharge when due, the following Liabilities, obligations and
commitments of Seller and its Affiliates (the “ Assumed
Liabilities ”):
|
|
(i)
|
all
Liabilities, obligations and commitments that Purchaser has
expressly assumed or agreed to assume under this Agreement
(including as contemplated by Section 5.04 hereof);
|
|
|
(ii)
|
all Liabilities
arising out of or relating to any product liability, breach of
warranty or similar claim for injury to Person or property due to
the use or misuse of any Product sold after the Closing Date or the
use or misuse of Acquired Assets which use or misuse occurred after
the Closing Date;
|
|
|
(iii)
|
all Liabilities
(excluding Cure Costs) that arise after the Closing Date under the
Assumed Contracts (other than obligations arising out of or
relating to a Default that occurred prior to the Closing Date);
and
|
|
|
(iv)
|
the Liability
to Customers and the Repurchase Liability, each of which shall be
deducted from the Purchase Price pursuant to Section
2.03(a)(i).
|
(b) Prior to the Closing Date,
Seller may make offers to repurchase tubes of Product from
wholesale customers at prices to be specified by Seller and shall
use commercially reasonable efforts to repurchase tubes of Product
with expiration dates prior to June 30, 2005. Seller agrees to
keep
12
Purchaser reasonably informed of its efforts and
progress in repurchasing tubes of Product. The number of tubes of
Product, regardless of expiration date, that such customers agree,
by written letter or notification delivered to the Seller on or
before June 25, 2004 (or as resolved in accordance with paragraphs
17 and 18 of the Sale Order), to return (which return shall be made
to the Purchaser after the closing of the Sale) at the prices
specified by Seller in its offers or at other prices mutually
agreed to by Seller and such customers, shall be referred to herein
as the “ Repurchase Tubes .” The aggregate
dollar amount required to repurchase the Repurchase Tubes at the
prices agreed upon by Seller and such customers shall be referred
to herein as the “ Repurchase Liability .” The
parties acknowledge and agree that the Repurchase Tubes shall be
destroyed and in no event shall the Repurchase Tubes be re-sold by
Seller or Purchaser.
(c) Notwithstanding any other
provision of this Agreement, except for the Assumed Liabilities
expressly specified in Section 2.02(a), Purchaser shall not assume,
or otherwise be responsible for, any Liabilities of Seller whether
liquidated or unliquidated, or known or unknown, whether arising
out of occurrences prior to, at or after the Closing Date (“
Excluded Liabilities ”), which Excluded Liabilities
include:
|
|
(i)
|
all Liabilities
arising out of or relating to any product liability, breach of
warranty or similar claim for injury to Person or property, whether
based on negligence, breach of warranty, strict liability,
enterprise liability or any other legal or equitable theory arising
from defects in products, due to the use or misuse of any Product
sold on or prior to the Closing Date or the use or misuse of the
Acquired Assets on or prior to the Closing Date;
|
|
|
(ii)
|
any Liability
to or in respect of any employees or former employees of
Seller;
|
|
|
(iii)
|
any Liability
of Seller in respect of any Tax (except as contemplated by Section
5.02 below); and
|
|
|
(iv)
|
Environmental
Claims arising from occurrences prior to the Closing
Date.
|
Section 2.03. Purchase
Price .
(a) Purchase Price . As full
and fair consideration for the Acquired Assets, Purchaser agrees
to:
|
|
(i)
|
deliver or cause to be delivered
to Seller at the Closing by wire transfer in immediately available
funds an amount equal to $38,850,000 minus (A) the dollar
amount, which shall be agreed upon by the parties on or before June
25, 2004 (or as resolved in accordance with paragraphs 17 and 18 of
the Sale Order), of any obligations of Seller to wholesalers and
chain warehouses for Product returned by such parties to Seller on
or before June 25, 2004 and not replaced by Seller with alternative
product or a return of purchase price on or before such date,
utilizing payment terms acceptable to these customers and Seller,
provided such payment terms shall not be below 90% of the original
net invoice price without Purchaser’s approval (the “
Liability to Customers ”); minus (B) the
Repurchase Liability; minus (C) an amount equal to
$4,100,000, such amount to be used by Purchaser (in whole or in
part, without recourse by
|
13
|
|
Seller to any amount not so used)
to compensate Purchaser for entering into the Supply Agreement,
dated as of May 14, 2004, between BMS and Purchaser (the “
Supply Agreement ”), of which $1,854,279 shall be paid
by Purchaser to BMS on or promptly following the Closing Date and
the remaining $2,245,721 shall be retained by the Purchaser;
minus (D) the value (based on Seller’s January 2004
Wholesale Acquisition Cost price of $42.32 per tube) of any tubes
of Product shipped by Seller between April 15, 2004 and June 25,
2004 in excess of 16,463 tubes of Product (provided that any tubes
of Product sold by Seller directly to physicians consistent with
past practice shall not be counted in this calculation) (such
amount, the “ Purchase Price ”); minus
(E) the Deposit; minus (F) the Escrow Amount. Seller and
Purchaser shall cooperate with each other to calculate and mutually
agree upon the amounts contemplated by clauses (A), (B) and (D)
above at least five (5) Business Days prior to the Closing
Date;
|
|
|
(ii)
|
deliver or
cause to be delivered to a separate bank account of Seller (the
“ Escrow Account ”), by wire transfer in
immediately available funds, the Escrow Amount, pending
determination of certain indemnification obligations of Seller as
set forth in Section 10.02. As evidenced by the letter agreement,
dated April 29, 2004, between Seller’s senior secured lenders
and Purchaser, Seller’s senior secured lenders have agreed
that Purchaser’s rights to any funds in the Escrow Account
pursuant to the terms of this Agreement are superior to the rights
of such lenders to, or liens held by such lenders on, any funds in
the Escrow Account. The parties agree that the Escrow Amount shall
be disbursed only with the written consent of Purchaser and Seller,
unless the Bankruptcy Court shall otherwise direct; and
|
|
|
(iii)
|
assume the
Assumed Liabilities as of the Closing.
|
(b) Earnest Money Deposit .
Purchaser has delivered to the Seller an amount equal to $1,500,000
(the “ Deposit ”). Interest earned on the
Deposit shall be credited to and become part of the Deposit
reflected as it is credited to such accounts. As evidenced by the
letter agreement, dated April 29, 2004, between Seller’s
senior secured lenders and Purchaser, Seller’s senior secured
lenders have agreed that Purchaser’s rights to any funds in
the Earnest Money Deposit account pursuant to the terms of this
Agreement are superior to the rights of such lenders to, or liens
held by such lenders on, any funds in the Earnest Money Deposit
account. The Deposit shall be disbursed in accordance with one of
the following provisions, whichever shall apply:
|
|
(i)
|
If the Closing
occurs, then at Closing the amount of the Deposit shall be credited
toward the Purchase Price and delivered to Seller;
|
|
|
(ii)
|
If this
Agreement is terminated pursuant to Section 9 of this Agreement
(other than a termination with respect to which the Deposit is
payable to Seller pursuant to clause (iii) below), then within two
(2) Business Days after such termination, the Deposit shall be
returned to Purchaser; or
|
|
|
(iii)
|
If (x) this Agreement is
terminated by Seller pursuant to Section 9.01(c) of this Agreement
and (y) as of the date of such termination Purchaser does not have
any right to terminate this Agreement pursuant to Section 9, then
the Deposit shall be paid to Seller as liquidated damages and
not
|
14
|
|
a penalty and as Seller’s
sole and exclusive remedy. The parties recognize that the
determination of damages in the event of a termination of this
Agreement pursuant to Section 9 will be difficult and that the
disbursement of the Deposit constitutes a reasonable estimate of
such actual damages, and therefore liquidated damages and not a
penalty.
|
(c) Supply Agreement .
Purchaser has informed Seller that it has a contingent right to
purchase a limited number of tubes of Product under the Supply
Agreement at discounts to the pricing previously disclosed to
Seller, for an aggregate potential savings of up to $515,000 in the
aggregate. Purchaser agrees that if the Closing Date shall be on or
before July 15, 2004, Purchaser shall pay 50% of the savings with
respect thereto (or an aggregate of $257,500) over to the Seller.
Purchaser shall use commercially reasonable efforts to effect the
Closing promptly and on or before July 15, 2004.
Section 2.04. Closing;
Deliveries .
(a) Closing . Provided that
the Sale Order shall have been entered and no stay with respect
thereto shall be in effect and the closing of the transactions
contemplated hereby (the “ Closing ”) is
permitted under the terms of the Sale Order, the Closing shall take
place at the offices of Latham & Watkins LLP, 12636 High Bluff
Drive, Suite 300, San Diego, California 92130 and on a date and
time (the “ Closing Date ”) to be mutually
agreed upon by Purchaser and Seller.
(b) Closing Deliveries by
Seller . At the Closing, Seller shall deliver or cause to be
delivered four (4) originals or facsimiles (with originals to
follow within forty-eight (48) hours after the Closing) of each of
the following, in each case duly executed by Seller, (A) the Bill
of Sale, (B) the Assignment of Copyrights, (C) the Assignment of
Trademarks, (D) the Assignment of Seller Patents, (E) the
Assignment of Internet Names, (F) the Assumption Agreement, (G) a
certificate, duly executed by an authorized officer of Seller, in
substantially the form attached hereto as Exhibit L (“
Seller’s Officer’s Certificate ”), (H) a
certified copy of the resolutions of the Board of Directors of
Seller approving the transactions contemplated hereby, (I) valid
and binding consents of all Persons whose consent was obtained
pursuant to Section 5.05(a)(i), (J) the Tube Liability Certificate,
and (K) such other documents, instruments and certificates as may
be appropriate to effect the transactions contemplated hereby as
Purchaser may reasonably request.
(c) Closing Deliveries by
Purchaser . At the Closing, Purchaser shall deliver or cause to
be delivered to Seller:
|
|
(i)
|
the Purchase
Price in immediately available U.S. dollars by electronic funds
transfer in the amounts and to the accounts of such entities as are
designated by Seller to Purchaser in writing not later than two (2)
Business Days prior to the Closing Date; and
|
|
|
(ii)
|
four (4)
originals or facsimiles (with originals to follow within
forty-eight (48) hours after the Closing) of each of the following,
in each case duly executed by Purchaser, (A) the Assignment of
Copyrights, (B) the Assignment of Trademarks, (C) the Assignment of
Seller Patents, (D) the Assignment of Internet Names, (E) the
Assumption Agreement, (F) a certificate, duly executed by an
authorized officer of Purchaser, in substantially the form attached
hereto as Exhibit M (“ Purchaser’s
Officer’s Certificate ”), (G) a certified copy of
the resolutions of the Board of Directors of Purchaser approving
the transactions contemplated hereby and (H) such other documents,
instruments and certificates as may be appropriate to effect the
transactions contemplated hereby as Seller may reasonably
request.
|
15
(d) Customer Liability and
Repurchase Liability . At the Closing, Seller shall provide to
Purchaser written confirmations from each of its four largest
wholesale customers of such customer’s calculation of the
Liability to Customers and Repurchase Liability relating to such
customer. To the extent Seller is unable to obtain any of such
confirmations, it shall provide Purchaser with a certificate,
signed by an officer of Seller (the “ Tube Liability
Certificate ”), that lists for each customer for which
Seller has not obtained a confirmation, Seller’s calculation
of Liability to Customer and Repurchase Liability for such customer
and such customer’s calculation (if the same has been
provided by such customer).
(e) Delivery of Documents .
All documents delivered at the Closing by the parties pursuant to
Sections 2.04(b) and 2.04(c)(ii) shall be dated as of the Closing
Date.
(f) Delivery of Certain Acquired
Assets . On the Closing Date, title to the Inventory, the
Regulatory Documentation, the Books and Records and the Marketing
Materials shall be transferred to Purchaser. Immediately following
the Closing, Seller will make the Inventory available for pick up
by Purchaser or its common carrier. In addition, promptly, but in
no event later than ten (10) days following the Closing Date,
Seller will deliver to Purchaser that portion of the Regulatory
Documentation comprised of the complete complaint, adverse event
and medical inquiry filings with respect to the Product. Promptly,
but in no event later than thirty (30) days following the Closing
Date, Seller will deliver the Books and Records, the Marketing
Materials and the balance of the Regulatory Documentation to
Purchaser. Seller shall bear the risk of loss to the Inventory, the
Regulatory Documentation, the Books and Records and the Marketing
Materials until they have been delivered to Purchaser or its common
carrier; thereafter, Purchaser shall bear all risk of loss
associated with such Acquired Assets and shall be solely
responsible for procuring adequate insurance to protect against
such loss. Seller shall continue to maintain adequate insurance
against loss associated with the Acquired Assets until they have
been delivered to Purchaser or its common carrier.
Section 2.05. Assumption of
Assumed Contracts .
The Sale Order will provide for the
assumption by Seller and the sale and assignment to Purchaser,
effective upon the Closing, of the Assumed Contracts such that as
of the Closing Date, Seller shall assume pursuant to Section 365(a)
of the Bankruptcy Code and sell and assign to Purchaser pursuant to
Sections 363(b), (f) and (m) and Section 365(f) of the Bankruptcy
Code each of the Assumed Contracts. The Assumed Contracts are set
forth on Exhibit E and identified by the date of the Assumed
Contracts (if available) and the other party or parties to such
Assumed Contract. The Cure Costs have been determined in good faith
by Seller based on Seller’s Books and Records and are as set
forth as of the date hereof on Schedule 2.05 of the
Disclosure Schedule. Seller shall be responsible for providing
notice to the non-debtor parties to all Assumed Contracts at least
30 calendar days prior to the Sale Hearing and shall make any
filings and appearances with the Bankruptcy Court as required by
the Bankruptcy Code or this Agreement. The Cure Costs shall be paid
by Seller. True and complete copies of the Assumed Contracts,
together with all amendments and supplements thereto and all
waivers of any terms thereof, have been made available to Purchaser
prior to the execution of this Agreement. Except as set forth on
Schedule 2.05(a) : (1) subject to payment of any Cure Costs,
and except for any default arising as a result of the commencement
of the Chapter 11 Case or as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect
on Seller, each Assumed Contract is valid, binding and in full
force and effect, and is enforceable by Seller, as applicable, in
accordance with its terms; (2) subject to payment of any Cure
Costs, and except for any default arising as a result of the
commencement of the Chapter 11 Case, Seller and, to the Knowledge
of Seller, each counterparty to any Assumed Contract, has performed
in all respects the obligations required to be performed by it to
date and
16
is not in default under each Assumed Contract to
which it is a party, except for such failure or failures to perform
which would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect on Seller and which
would not prevent the assumption and assignment of the contract to
Purchaser; (3) subject to payment of any Cure Costs and, except for
any default arising as a result of the commencement of the Chapter
11 Case, Seller has not received any notice of default under any
Assumed Contract to which it is a party, except as would not,
individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect on Seller and there exists no event which,
with or without the giving of notice or lapse of time or both,
would constitute such default thereunder by Seller. Except as a
result of the Chapter 11 Case or as set forth on Schedule
2.05(a) of the Disclosure Schedule, as of the date hereof,
Seller is not in negotiations to amend, or contemplating the
amendment of, any Assumed Contract. Except as set forth in the
Shire License Agreement, Seller is not a party to or bound by any
non-competition agreement that materially impairs its ability to
operate the Business. Purchaser shall use commercially reasonable
efforts to provide, to the extent necessary, evidence of its
ability to provide adequate assurance of future performance of the
obligations under the Assumed Contracts as required by Section 365
of the Bankruptcy Code.
Section 2.06. Risk of Loss
.
Except as otherwise provided in
Section 2.04(e), (a) until the Closing, any loss of or damage to
the Acquired Assets from fire, casualty or any other occurrence
shall be the sole responsibility of Seller and (b) at the Closing,
title to the Acquired Assets shall be transferred to Purchaser and
Purchaser shall thereafter bear all risk of loss associated with
the Acquired Assets including, without limitation, any loss from an
environmental impact arising from the Release or consumption of the
Product that occurs after the Closing, and shall be solely
responsible for procuring adequate insurance to protect the
Acquired Assets against any such loss.
Section 2.07. Bankruptcy Court
Approval .
Notwithstanding anything contained
herein to the contrary, performance by Seller of its obligations
under this Agreement are expressly conditioned upon entry of the
Sale Order, that shall not have been stayed by the Closing, by the
Bankruptcy Court expressly approving such performance.
SECTION 3.
REPRESENTATIONS AND WARRANTIES OF
SELLER
Seller represents and warrants to
Purchaser, as of the date hereof and the Closing Date (except as
otherwise expressly provided herein), subject to such exceptions as
are disclosed in the disclosure schedule supplied by Seller (the
“ Disclosure Schedule ”), which Disclosure
Schedule shall be deemed to be representations and warranties of
Seller as if made herein, as follows:
Section 3.01. Organization,
Etc .
Seller is a corporation duly
incorporated, validly existing and in good standing under the laws
of the State of Delaware. Seller is duly authorized to conduct its
business and is in good standing in each jurisdiction where such
qualification is required, except for any jurisdiction where
failure to so qualify would not have a Material Adverse Effect on
Seller. Seller has full power and authority, and holds all permits
and authorizations, to carry on its business, including the
Business, and to own and use the assets and properties owned and
used by it, including the Acquired Assets, except where the failure
to have such power and authority or to hold such permits or
authorizations would not have a Material Adverse Effect on Seller.
Schedule 3.01 sets forth a true and complete list of all
such permits and authorizations, indicating those permits and
authorizations that are non-transferable.
17
Section 3.02. Authority;
Execution and Delivery; Enforceability .
Subject to entry of the Sale Order,
Seller has all requisite power and authority and has taken all
actions necessary to execute and deliver this Agreement and all
Related Instruments to be executed and delivered by Seller, to
consummate the transactions contemplated hereby and thereby and to
perform its obligations hereunder and thereunder, and no other
proceedings on the part of Seller are necessary to authorize this
Agreement or any Related Instrument to be executed and delivered by
Seller or to consummate the transactions contemplated hereby or
thereby. Subject to the provisions of the Bankruptcy Code and the
entry and effectiveness of the Sale Order: this Agreement has been
duly and validly executed and delivered by Seller and, assuming
that this Agreement has been duly authorized, executed and
delivered by Purchaser, constitutes, and each Related Instrument
that is to be executed and delivered by Seller will constitute when
executed and delivered by Seller, assuming that such Related
Instrument has been duly authorized, executed and delivered by
Purchaser, if and as applicable, a valid and binding obligation of
Seller, enforceable against Seller in accordance with its
terms.
Section 3.03. Consents and
Approvals; No Violations .
(a) Subject to entry of the Sale
Order, the execution and delivery by Seller of this Agreement and
any Related Instruments, and the performance by Seller of its
obligations under this Agreement and any Related Instrument to be
executed and delivered by Seller and the consummation of the
transactions contemplated hereby and thereby will not: (i) conflict
with or violate or breach any of the terms, conditions or
provisions of any organizational document of Seller; (ii) conflict
with or result in a violation or breach of, or constitute a default
(or an event which, with or without notice or lapse of time or
both, would constitute a breach or default) under, or result in the
termination of, or accelerate the performance required by, or cause
the acceleration of the maturity of any debt or obligation pursuant
to, any Contract to which Seller is a party or by which Seller or
any of the Acquired Assets is bound, or result in the creation or
imposition of any Lien upon any of the Acquired Assets, other than
Permitted Liens; or (iii) violate or conflict with any Requirements
of Laws applicable to Seller or the Acquired Assets, except in the
case of clauses (ii) or (iii) for violations, breaches or defaults
which would not, individually or in the aggregate, reasonably be
expected to result in a Material Adverse Effect with respect to
Seller (any of (i), (ii) and (iii), a “ Conflict
”).
(b) No permit, notice, consent,
approval, or registration, declaration or filing with, any Person
(so as not to trigger any Conflict) is necessary for the execution
and delivery of this Agreement or any Related Instrument by Seller
or the consummation by Seller of the transactions contemplated by
this Agreement or any Related Instrument to be executed and
delivered by Seller, except for permits, notices, consents,
approvals or authorizations of, or declarations or filings with,
t